吉非替尼联合顺铂对肺癌细胞增殖的协同抑制作用

Synergistic effect of gefitinib and cisplatin on proliferation of lung cancer cell line

目的:观察表皮生长因子受体酪氨酸激酶抑制剂吉非替尼(Gefitinib,G)与顺铂(Cisplatin,DDP)联合对肺癌细胞株A549增殖抑制的协同效应。方法:采用四甲基偶氮唑蓝(MTT)法检测不同浓度吉非替尼单药、顺铂单药以及两药联用对肺癌细胞株A549的抑制程度,并应用两药相互作用指数评价药物的联合效应。结果:在药物作用时间足够时,两药联用相对单药组能显著地提高肿瘤细胞的抑制率,并且抑制效率随药物浓度的增加而提高。当作用时间≥48h时,联用组A值相对于单药组明显降低(P<0.05)。联用对肿瘤细胞增长的抑制作用在48h时较24h明显增高(P<0.05),并随着时间的延长呈现递增趋势,至72h后逐渐进入平台期(P>0.05)。两药协同效应在作用24h时表现不明显,在48h后才开始出现(CDI<1)。结论:在药物作用时间足够时,吉非替尼与顺铂联用对肺癌细胞的增殖具有协同抑制效应,可为临床应用提供参考。

Objevtive：To evaluate the synergistic effect of gefitinib and cisplatin on inhibition of proliferation of lung cancer cell line A549. Methods：The effect of gefitinib, cisplatin, and gefitinib in combination with cisplatin on lung cancer cell line A549 were detected by MTT assay, and the synergistic effect was analysed by the coefficient of drug interaction. Results：After 48h treatment, the combination of gefitinib and cisplatin inhibited the proliferation of A549 cells in a time - and dose - dependent manner. Conclusion： The single agent of gefitinib and cisplatin can inhibit the proliferation of A549 cells, and they have obvious synergistic activity. The combined EGFR - targeting thera py on lung cancer is worth of further exploration.